Second-line afatinib increases progression-free survival (PFS) in metastatic head and neck cancer

Second-line afatinib increases progression-free survival (PFS) in metastatic head and neck cancer

EMJ

5 years
1,263 Views
Share Report
Want to watch this again later?
Sign in to add this video to a playlist. Login
0 0
Category:
Description:
During a press conference at ESMO 2014, Dr Jean-Pascal Machiels, Cliniques Universitaires St. Luc, Brussels, Belgium, presents the results of a Phase III study looking at the impact of afatinib versus methotrexate upon progression-free survival in patients with head and neck cancer after failure of platinum-based chemotherapy.
Up Next Autoplay